Comprehensive Clinical Analysis of Gallbladder Neuroendocrine Neoplasms: A Large-Volume Multicenter Study During One Decade
- PMID: 35849293
- DOI: 10.1245/s10434-022-12107-w
Comprehensive Clinical Analysis of Gallbladder Neuroendocrine Neoplasms: A Large-Volume Multicenter Study During One Decade
Abstract
Background: This study aimed to comprehensively investigate the clinicopathologic characteristics and therapeutic situations of gallbladder neuroendocrine neoplasms (GB-NENs) in the real world via a multicenter, large-scale cohort study.
Methods: The study searched for patients in 143 hospitals in China and enrolled 154 patients with GB-NENs diagnosed in 40 hospitals between 2004 and 2021. Clinicopathologic characteristics and therapeutic approaches were analyzed retrospectively.
Results: The median age at the initial diagnosis of the patients with GB-NENs was 63 years (range 33-83 years), and 61.7% of the patients were women. Tumor-node-metastasis staging classified 92 patients as stage 3 or above. Based on the 2019 World Health Organization classification, 96 cases (62.3%) were confirmed pathologically as poorly differentiated neuroendocrine carcinomas, 13 cases (8.4%) as well-differentiated neuroendocrine tumors, and 45 cases as mixed neuroendocrine-non-neuroendocrine neoplasms. The liver was the most frequent metastatic site. Immunohistochemistry showed that synaptophysin was most frequently positive (80.4%), followed by chromogranin A (61.7%), and CD56 (58.4%). Computed tomography and magnetic resonance imaging showed more common clear boundaries (25/39 cases) and invasive growth features (27 cases). None of these cases had an accurate diagnosis before surgery, with a misdiagnosis rate of 100%. Surgical resection is the main treatment, and platinum-based chemotherapeutic regimens were preferred as adjuvant therapies for patients with GB-NENs. The available survival data for 74 patients showed an overall survival rate of 59% at 1 year, 33% at 3 years, and 29% at 5 years. No significant difference was found between the patients treated with and those treated without adjuvant chemotherapy.
Conclusions: Gallbladder neuroendocrine neoplasms have high malignancy and a poor prognosis. Importantly, this large-scale cohort study significantly improves our understanding of GB-NENs and will benefit the exploration of its mechanism and treatment modes. Further investigation is necessary to explore the management of this disease.
© 2022. Society of Surgical Oncology.
Comment in
-
ASO Author Reflections: Comprehensive Clinical Analysis of Gallbladder Neuroendocrine Neoplasms.Ann Surg Oncol. 2022 Nov;29(12):7631. doi: 10.1245/s10434-022-12121-y. Epub 2022 Jul 6. Ann Surg Oncol. 2022. PMID: 35794367 No abstract available.
Similar articles
-
[Clinicopathological features of pancreatic neuroendocrine neoplasms: a retrospective analysis of 64 cases].Zhonghua Zhong Liu Za Zhi. 2014 Apr;36(4):287-93. Zhonghua Zhong Liu Za Zhi. 2014. PMID: 24989916 Chinese.
-
[Clinicopathological features of colorectal neuroendocrine neoplasms and prognostic significance of WHO staging system].Zhonghua Bing Li Xue Za Zhi. 2013 Mar;42(3):191-6. doi: 10.3760/cma.j.issn.0529-5807.2013.03.011. Zhonghua Bing Li Xue Za Zhi. 2013. PMID: 23769440 Chinese.
-
Neuroendocrine Carcinoma of Gall Bladder: A Series of 19 Cases with Review of Literature.J Gastrointest Cancer. 2015 Dec;46(4):356-64. doi: 10.1007/s12029-015-9745-9. J Gastrointest Cancer. 2015. PMID: 26208508 Review.
-
Neuroendocrine neoplasms of the gallbladder: early detection and surgery is key to improved outcome.Langenbecks Arch Surg. 2022 Feb;407(1):197-206. doi: 10.1007/s00423-021-02256-z. Epub 2021 Jul 8. Langenbecks Arch Surg. 2022. PMID: 34236488
-
Mixed neuroendocrine-non-neuroendocrine neoplasm of the gallbladder: case report and literature review.Diagn Pathol. 2022 Jun 17;17(1):51. doi: 10.1186/s13000-022-01231-6. Diagn Pathol. 2022. PMID: 35715834 Free PMC article. Review.
Cited by
-
Comparative prognosis and risk assessment in gallbladder neuroendocrine neoplasms versus adenocarcinomas.Front Endocrinol (Lausanne). 2024 Feb 8;15:1326112. doi: 10.3389/fendo.2024.1326112. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 38390209 Free PMC article.
-
Case Report: Diagnosing and treating gallbladder neuroendocrine neoplasms through comparative analysis: a case series and literature review.Front Oncol. 2025 Jun 16;15:1606850. doi: 10.3389/fonc.2025.1606850. eCollection 2025. Front Oncol. 2025. PMID: 40589647 Free PMC article.
-
Targeted gene sequencing and bioinformatics analysis of patients with gallbladder neuroendocrine carcinoma: A case report.World J Gastrointest Oncol. 2025 Jan 15;17(1):100757. doi: 10.4251/wjgo.v17.i1.100757. World J Gastrointest Oncol. 2025. PMID: 39817132 Free PMC article.
References
-
- Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063–72. - PubMed
-
- Kunz PL. Carcinoid and neuroendocrine tumors: building on success. J Clin Oncol. 2015;33:1855–63. - PubMed
-
- Janson ET, Sorbye H, Welin S, et al. Nordic guidelines 2010 for diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours. Acta Oncol. 2010;49:740–56. - PubMed
-
- Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97:934–59. - PubMed
-
- Albores-Saavedra J, Batich K, Hossain S, et al. Carcinoid tumors and small cell carcinomas of the gallbladder and extrahepatic bile ducts: a comparative study based on 221 cases from the surveillance, epidemiology, and end results program. Ann Diagn Pathol. 2009;13:378–83. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials